Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, September 5, 2018
NANOBIOTIX half year results for the six months ended June 30, 2018
Friday, July 27, 2018
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank
Friday, June 22, 2018
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
Wednesday, June 6, 2018
NANOBIOTIX' Management Statement on Recent Share Price Variation
Friday, May 4, 2018
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
Wednesday, April 18, 2018
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Wednesday, April 11, 2018
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab
Friday, March 30, 2018
Nanobiotix 2017 Annual Results
Monday, January 22, 2018
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting
Thursday, January 11, 2018
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: